TOP > 外国特許検索 > METHOD FOR USING SYT7, MFSD4, AND ETNK2 EXPRESSION LEVELS TO DETECT METASTASIS OF GASTRIC CANCER TO LIVER, DETECTION KIT, METHOD FOR SCREENING MOLECULAR TARGETED THERAPEUTIC AGENT, AND PHARMACEUTICAL COMPOSITION

METHOD FOR USING SYT7, MFSD4, AND ETNK2 EXPRESSION LEVELS TO DETECT METASTASIS OF GASTRIC CANCER TO LIVER, DETECTION KIT, METHOD FOR SCREENING MOLECULAR TARGETED THERAPEUTIC AGENT, AND PHARMACEUTICAL COMPOSITION コモンズ

外国特許コード F160008842
整理番号 NU-657
掲載日 2016年9月1日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP063956
国際公開番号 WO 2016181979
国際出願日 平成28年5月11日(2016.5.11)
国際公開日 平成28年11月17日(2016.11.17)
優先権データ
  • 特願2015-097939 (2015.5.13) JP
発明の名称 (英語) METHOD FOR USING SYT7, MFSD4, AND ETNK2 EXPRESSION LEVELS TO DETECT METASTASIS OF GASTRIC CANCER TO LIVER, DETECTION KIT, METHOD FOR SCREENING MOLECULAR TARGETED THERAPEUTIC AGENT, AND PHARMACEUTICAL COMPOSITION コモンズ
発明の概要(英語) Provided are a detection method for predicting the metastasis of gastric cancer to the liver, a detection kit, and a method for screening a medicine which selectively acts on liver metastasis. By targeting SYT7, MFSD4, and ETNK2, the expression of which specifically changes during metastasis of gastric cancer to the liver, postoperative liver metastasis can be predicted or a molecular targeted therapeutic agent can be screened.
従来技術、競合技術の概要(英語) BACKGROUND ART
Gastric Japan, China, such as Korea Asia, South America in cancers. As a result of the cancer mortality in Japan is viewed, the mortality of gastric cancer, lung cancer in men but reduced year after year followed by the second position 2, in women in the colon cancer, lung cancer and then, the mortality rate of the first position and the 3 (2012 years according to statistics.). With the widespread use of cancer screening, early detection is advanced and the mortality rate is decreased due to gastric cancer. However, is still poor prognosis and progress of gastric cancer, gastric cancer high morbidity in important diseases to be overcome in japan.
Largely influences the prognosis of gastric cancer recurrence metastasis. In the present state of having gastric cancer distant metastases treated collectively, not also distinguished by its course of treatment. However, may be in the recurrence of gastric cancer metastasis, peritoneal-seeding transition, hematogenous metastasis, lymph node metastasis that is completely different from the one of paths 3.
The resulting free cancer cells HCCs from engraftment, growth and metastases may be formed of a multi-step and required and, adhesion molecules, proteolytic enzymes, growth factors, angiogenic factors, such as chemokines is involved in many molecules have been reported. 3 In stomach cancer in metastasis relapse is greatly different from the one path is, unlike the molecules involved in metastasis, a cancer cell metastasis differs greatly from the properties of the thought. Nevertheless, different mechanisms established metastatic foci along two paths 3 as remote metastases are carried out in the same treatment of metastatic cancer to the difficulty of complete healing is believed to contribute.
Gastric cancer recurrence risk of gastric cancer recurrence for chemotherapy course is performed. The current is used as a standard regimen, and the mechanism of action of a DNA synthesis inhibitor administration of S-1 based therapy. Gastric cancer progression is, as a result of the large-scale cohort study, as an adjuvant therapy to post-prostatectomy stomach by oral treatment S-1 was observed, the standard treatment of post-surgical S-1 and the medicine. S-1 cell proliferation is generally raised with agents and cancer, gastric cancer metastasis does not specifically act on. Actually proceeds S-1 monotherapy significantly extended the survival time of a stomach cancer patient and to be a main, a reduced rate of recurrence and peritoneal-seeding, including liver metastasis in lymph node metastasis by hematogenous metastatic and difficult to say that the controlled.
Recurrence of gastric cancer metastasis to other organs such as the blood flow as a form just a hematogenous metastasis can be transferred to, then often a peritoneal-seeding metastasis. In the case of gastric cancer among hematogenous metastatic spread hepatic metastasis often metastasize to the liver. Recurrence to valid and will not be much medicine S-1, the subjective symptom is not likely an early recurrence of liver metastases, post-operative follow-up to perform the therapy in gastric cancer has been important.
In recent years, such as a sequencer and the next generation microarray by exhaustive gene analysis method, the identification of a tumor marker having high specificity is being performed. Gastric cancer with respect to predicting recurrence, disclosed a method for detecting a (Patent Document 1-3). In addition, irrespective of the cancer at high risk of hepatic metastases but is reported with respect to markers, specific for gastric cancer prediction of hepatic metastases is not advanced ahead of the studies with respect to markers (patent document 4).
In addition, in the treatment of cancer is, possible to reduce the side effects of the therapeutic agent of the molecular targets have been actively developed. The therapeutic agent is a molecular target, such as cancer cells, the nature of the diseased cells captured at the molecular level, and an expressed protein on the surface of the target gene or the like which is configured to act efficiently as refers to an agent. Gastric cancer therapeutic agent is a small number of molecular targets for still, gastric Trastuzumab positive HER2 only with respect to the surface are a national approval. Further, advanced gastric cancer in the United States (ramucirumab) ramucirumab is approved.
In addition, with respect to gastric cancer progression, recurrence transition format as described above different molecular target therapeutic agent different from each other have been developed but, in particular liver metastasis typified by hematogenous metastatic effective molecular target therapeutic agent does not have been developed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
  • 発明者(英語)
  • KANDA Mitsuro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
名古屋大学の公開特許情報を掲載しています。ご関心のある案件がございましたら、下記まで電子メールでご連絡ください。

PAGE TOP

close
close
close
close
close
close